Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Recurrence
Description
The return of a sign, symptom, or disease after a remission. MeSH
Hierarchy View
Subtype Terms (2)
Symptom Flare Up
1 experimental drug
Phase 4 Indicated Drugs (14)
Phase 3 Indicated Drugs (35)
Phase 2 Indicated Drugs (28)
Phase 1 Indicated Drugs (15)
Other Experimental Indicated Drugs (8)
Organization Involved with Phase 4 Indications (113)
Badalona Hospital Germans Trias i Pujol
Children's Hospital Los Angeles
Dawnrays Pharmaceutical (Holdings) Limited
Eastern Hepatobiliary Surgery Hospital
First People's Hospital of Hangzhou
Guangzhou Pharmaceucal Company Limited
Hoosier Cancer Research Network
Huazhong University of Science and Technology
Korean Society of Hematology Thrombosis Working Party
National Cancer Institute (NCI)
National Cheng Kung University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Drug Abuse (NIDA)
National Malaria and Leishmaniasis Control Program, Afghanistan
North Suffolk Mental Health Association
Qidong Gaitianli Medicines Co., Ltd
Second Military Medical University
Shandong first medical University
Shandong Province Qianfoshan Hospital
Smerud Medical Research Denmark
Organization Involved with Phase 3 Indications (199)
ABX advanced biochemical compounds GmbH
Advanced Nuclear Medicine Ingredients
Amercian Australian Asian Adrenal Alliance (A5)
Amhara Regional Health Bureau, Amhara Region
Anhui College of Traditional Chinese Medicine
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
Aristotle University of Thessaloniki
Assistance Publique - Hôpitaux de Paris
Australia New Zealand Gynaecological Oncology Group
Canadian Institutes of Health Research (CIHR)
Canadian Stroke Consortium (CSC)
Centre Catherine de Sienne - Nantes
Centre hospitalier de Mulhouse
Centre Hospitalier de Saint-Brieuc
Centre Hospitalier Sainte-Anne
Chinese Academy of Medical Sciences
Drugs for Neglected Diseases Initiative
Eastern Cooperative Oncology Group
European Network for the Study of Adrenal Tumors (ENS@T)
European Organisation for Research and Treatment of Cancer
First People's Hospital of Chenzhou
Fondazione Neoplasie Sangue Onlus
Fundação de Amparo à Pesquisa do Estado de São Paulo
Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (GETAID)
Groupe Hospitalier Paris Saint Joseph
Hospital Universitario Lucus Augusti
Innovatiefonds Zorgverzekeraars
Institut de Cancérologie de Lorraine
Institut de Cancerologie de l'Ouest Paul Papin
Institute of Tropical Medicine, Belgium
Institut National de la Santé Et de la Recherche Médicale, France
International Breast Cancer Study Group
International Myeloma Foundation (IMF)
Jhaver Research Foundation Limited
Katholieke Universiteit Leuven
Lotte & John Hecht Memorial Foundation
Multiple Sclerosis Society of Canada
National Cancer Institute, France
National Institute of Nursing Research (NINR)
National Institutes of Health (NIH)
National University of Singapore
New York City Department of Health and Mental Hygiene
People's Liberation Army of China
Regional Hospital West Jutland
Royal Hobart Hospital, TAS, Australia
Serum Institute of India Pvt. Ltd.
Stichting Geriatrische Oncologie Nederland
Stichting voor Patienten met Kanker aan het Spijsverteringskanaal
The Canadian College of Naturopathic Medicine
The Physicians' Services Incorporated Foundation
Tigray Regional Health Bureau, Tigray Region
Translational Research Informatics Center, Kobe, Hyogo, Japan
Organization Involved with Phase 2 Indications (154)
All India Institute of Medical Sciences
Azienda Ospedaliera Universitaria Policlinico
Case Western Reserve University
Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète
Ciusss de L'Est de l'Île de Montréal
Clinica Universidad de Navarra
Crohn's and Colitis Foundation
Dermatology Consulting Services, High Point NC
Gruppo Italiano Malattie EMatologiche dell'Adulto
Hangzhou Hospital of Traditional Chinese Medicine
Icahn School of Medicine at Mount Sinai
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Intergroupe Francophone du Myelome
International organization for the study of inflammatory bowel disease (IOIBD)
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Krankenhaus der Barmherzigen Schwestern Linz
Ludwig Institute for Cancer Research
Massachusetts Institute of Technology
Methodist Cancer Center, Houston, Texas
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
Oregon Health and Science University
Postgraduate Institute of Medical Education and Research
Royal Marsden Hospital NHS Trust
Russian Academy of Medical Sciences
Shanghai Armed Police Hospital
Shanghai Xuhui District Central Hospital
Shijiazhuang Pharma Group (CSPC)
University Hospital of Mont-Godinne
University of California, Los Angeles
University of California, San Diego
University of Colorado, Denver
University of North Carolina at Chapel Hill
University of Picardie Jules Verne
Urological Institute of Northeastern New York
Virginia Clinical Research, Inc.
ZonMw: The Netherlands Organisation for Health Research and Development
Organization Involved with Phase 1 Indications (54)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Brain & Spine Surgeons of New York
Children's National Medical Center
China Academy of Chinese Medical Sciences
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
French Innovative Leukemia Organisation
GeneScience Pharmaceuticals Co., Ltd.
Hebei Senlang Biotechnology Inc., Ltd.
Organization Involved with Other Experimental Indications (39)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
